Ph1/2 study of efficacy of TNG260 in combo with STK11-Mutated Solid Tumors
Phase I/II Clinical Trial
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors (TNG260-C101)